Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2017
Principal Executive Office: Boca Raton, FL
This filing discloses a material event regarding the Company's investigational product, TX-004HR, an applicator-free estradiol vaginal softgel capsule intended for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia) associated with vulvar and vaginal atrophy (VVA) due to menopause.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory developments and does not contain financial statement data.
Material Changes and Regulatory Events
- FDA Complete Response Letter (CRL): On May 8, 2017, the Company received a CRL from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for TX-004HR.
- Primary Concern: The FDA identified a lack of long-term endometrial safety data beyond the 12 weeks studied in the pivotal phase 3 Rejoice Trial as the only approvability concern.
- Safety Findings: No cases of endometrial hyperplasia were observed in the Rejoice Trial at the end of week 12 for all doses studied.
- Non-Issues: The CRL did not identify issues related to the efficacy of TX-004HR, nor did it raise approvability issues regarding chemistry, manufacturing, and controls.
Outlook, Management Commentary, and Risks
Management Action: The Company intends to meet with the FDA as soon as possible to discuss the concerns raised in the CRL.
Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ due to various risks.
Key Risks Identified:
- Ability to resolve FDA deficiencies and the timeframe for such resolution.
- Uncertainty regarding the preparation and acceptance of an amended NDA.
- Ability to maintain or increase sales of existing products.
- Need for additional financing to develop and commercialize hormone therapy candidates.
- Length, cost, and uncertain results of clinical trials.
- Potential adverse side effects or safety risks.
- Reliance on third parties for clinical trials, R&D, and manufacturing.
- Reimbursement availability from government and insurance entities.
- Product liability lawsuits and regulatory influences.
- Stock price volatility and ownership concentration.
Investor Verification Checklist
- Verify the specific requirements for the additional long-term endometrial safety data requested by the FDA.
- Monitor the timing and outcome of the Company's upcoming meeting with the FDA.
- Assess the Company's cash runway and ability to fund the required additional studies or amended NDA preparation.
- Review the Company's most recent Form 10-K and 10-Q for detailed financial position and risk factors.
- Track the status of the Company's other product candidate, TX-001HR, as mentioned in the risk factors.